SCHEMBL718231

SCHEMBL718231

COC(=O)c1ccc(NC(c2cc3ccc(OC)cc3o2)C2CCCCC2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.50
RAB9A P51151 3/20 0.50
HPGD P15428 3/20 0.50
KDM4E B2RXH2 2/20 0.50
HSD17B10 Q99714 1/20 0.50
NPC1 O15118 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
EPHX2 P34913 1/20 0.42
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
GBA1 P04062 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
HPGDS O60760 3/20 0.41
GAA P10253 1/20 0.41
MAOB P27338 1/20 0.41
MAPK1 P28482 2/20 0.40
PLAU P00749 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL720269 0.92 ALDH1A1 (0.50) ALDH1A1RAB9AHPGDKDM4EHSD17B10
SCHEMBL720105 0.86 ALDH1A1 (0.47) ALDH1A1RAB9AHPGDKDM4EHSD17B10
SCHEMBL720111 0.84 ALDH1A1 (0.43) ALDH1A1RAB9AHPGDKDM4EHSD17B10
SCHEMBL717279 0.80 GCG (0.44) ALDH1A1RAB9AHPGDKDM4EHSD17B10
SCHEMBL719390 0.79 NPC1 (0.45) ALDH1A1RAB9AHPGDKDM4EHSD17B10
SCHEMBL718424 0.77 HSD17B10 (0.41) ALDH1A1RAB9AHPGDKDM4EHSD17B10
SCHEMBL722458 0.75 NR1H4 (0.45) ALDH1A1RAB9ANPC1SMN1; SMN2EPHX2
SCHEMBL719470 0.75 RCE1 (0.53) RAB9AKDM4ENPC1SMN1; SMN2MEN1
SCHEMBL28290816 0.72 ALDH1A1 (0.52) ALDH1A1NPC1SMN1; SMN2EPHX2MEN1
SCHEMBL720543 0.72 NPC1 (0.52) ALDH1A1RAB9AKDM4ENPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP ALDH1A1 504/4885RAB9A 2454/4885HPGD 486/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP ALDH1A1 504/4885RAB9A 2454/4885HPGD 486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.